SAM
ELDN icon

Seelaus Asset Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Seelaus Asset Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-833
Closed -$15K – 169
2019
Q2 		$15K Buy
833
+277
+50% +$12.1K 0.01% 160
2019
Q1 		$40K Buy
+556
New +$36.9K 0.04% 160

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Seelaus Asset Management's ELDN Position: Q3 2019 in Review

Seelaus Asset Management sold out of Eledon Pharmaceuticals (ELDN) in Q3 2019, closing a stake of 833 shares — an estimated $15K sold.

Seelaus Asset Management first reported a position in ELDN in Q1 2019 and held it in 2 quarters. The position peaked at $40K in Q1 2019. 15 funds tracked by Wall St. Rank hold ELDN as of Q3 2019.

  • Seelaus Asset Management reported no remaining Eledon Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Seelaus Asset Management sold 833 Eledon Pharmaceuticals shares in Q3 2019, an estimated $15K.
  • Seelaus Asset Management first reported a position in Eledon Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Seelaus Asset Management's Eledon Pharmaceuticals position peaked at $40K in Q1 2019.
  • 15 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2019.

Based on Seelaus Asset Management's 13F filing for Q3 2019, filed 8 Nov 2019.